Related Experiment Video
Updated: Feb 11, 2026

Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
Published on: June 6, 2020
Transcobalamin receptor defect: Identification of two new cases through positive newborn screening for
Fady Hannah-Shmouni1, Vivian Cruz1, Andreas Schulze1,2
1Division of Clinical and Metabolic Genetics, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada.
Insights
Likely pathogenic variants in CD320 cause transcobalamin receptor defect, a rare inborn error of cobalamin metabolism. Long-term outcomes show these patients remain asymptomatic with normal neurodevelopment after early treatment.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Transcobalamin receptor defect, caused by CD320 variants, is a recently identified inborn error of cobalamin metabolism.
- Limited clinical and biochemical outcome data exist for this rare condition.
Observation:
- Two asymptomatic cases were identified via newborn screening for propionic/methylmalonic aciduria.
- Patients received oral cyanocobalamin (1 mg/day), normalizing biochemical abnormalities.
- Genetic analysis confirmed a known pathogenic CD320 variant (c.262_264GAG; p.Glu88del).
Findings:
- Both patients remain asymptomatic with normal neurodevelopment for over 6 years.
- Early oral cyanocobalamin treatment led to a favorable long-term outcome.
- This study expands the known cases and long-term follow-up data for transcobalamin receptor defect.
Implications:
- Transcobalamin receptor defect should be considered in newborns with positive newborn screening for methylmalonic acidurias.
- Early diagnosis and treatment of CD320-related disorders are crucial for preventing neurological complications.
- These findings provide a reassuring outlook for patients with this rare metabolic disorder.
Abstract:
Likely pathogenic variants in CD320 cause transcobalamin receptor defect, a recently discovered inborn errors of cobalamin metabolism. Only 12 cases have been reported to date. There are no long-term clinical and biochemical outcome reports since its first description. In this report, we present two new cases and report their long-term treatment outcome. Two asymptomatic cases were identified through a positive newborn screening for propionic/methylmalonic aciduria. Biochemical abnormalities were normalized on a short course of oral cyanocobalamin (1 mg/day). Direct sequencing of CD320 identified a known pathogenic variant (c.262_264GAG; p.Glu88del) confirming the diagnosis of transcobalamin receptor defect. To date, both patients remain asymptomatic with normal neurodevelopment more than 6 years. Our two new cases with transcobalamin receptor defect due to pathogenic variants in CD320 further expand our knowledge and provide a reassuring long-term good neurodevelopmental outcome. Identification of additional cases requires the consideration of transcobalamin receptor defect in the differential diagnosis of newborns with confirmed positive newborn screening for methylmalonic acidurias.
Related Concept Videos
Long-term Depression
Predicting Reaction Outcomes
Lumber Defects
Shakes are minor fractures that run along or across the wood's annual rings, while wane is...
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Position-effect Variegation
Internal Receptors

